European Monitoring Centre for Drugs and Drug Addiction. (2022) Report on the risk assessment of 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (as amended). Luxembourg: Publications Office of the European Union. Risk assessment 34. DOI: 10.2810/71344.
| Preview | Title | Contact |
|---|---|---|
|
PDF (Report on the risk assessment of 3-MMC)
1MB |
This publication presents the data and findings of the risk assessment on 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC), carried out by the extended Scientific Committee of the EMCDDA on 18 November 2021. On the basis of the Risk Assessment Report, on 18 March 2022, the Commission decided that 3-MMC should be included in the definition of 'drug', in the Annex to Framework Decision 2004/757/JHA.
[See also, EMCDDA release: European Commission adopts measures to control two harmful new drugs amidst health concerns and surge in supply]
E Concepts in biomedical areas > Pharmacology and toxicology
J Health care, prevention, harm reduction and treatment > Risk and needs assessment > Risk assessment
MM-MO Crime and law > Substance use laws > Drug laws
VA Geographic area > Europe
VA Geographic area > Europe > Ireland
Repository Staff Only: item control page